Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis

Ling Cao; Yong-Jing Yang; Jian-Dong Diao; Xu-He Zhang; Yan-Ling Liu; Bo-Yu Wang; Zhi-Wen Li; Shi-Xin Liu

doi:10.18632/oncotarget.26009

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis

PDF | How to cite

Oncotarget. 2018; 9:32273-32273. https://doi.org/10.18632/oncotarget.26009

Metrics: PDF 1431 views | ?

Ling Cao^1,*, Yong-Jing Yang^1,*, Jian-Dong Diao², Xu-He Zhang¹, Yan-Ling Liu¹, Bo-Yu Wang¹, Zhi-Wen Li³ and Shi-Xin Liu¹

¹ Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People’s Republic of China
² Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun 130012, People’s Republic of China
³ Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin, 130021, People’s Republic of China
^* These authors contributed equally to this work

Published: August 14, 2018

This article has been corrected: The correct affiliation is given below:

² Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun 130012, People’s Republic of China

Original article: Oncotarget. 2017; 8:90308-90314. DOI: https://doi.org/10.18632/oncotarget.19856.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26009

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis